Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 193 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Having a Heart Attack May Make Breast Cancer Grow Faster August 17, 2020 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Family Brings Joy & Raises Money With Their Extravagant Christmas Light... December 11, 2021 Advancing Patient Care Through Focused Innovation April 16, 2018 Load more HOT NEWS FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... The (un)usual suspects – how early detection research embraces interdisciplinary science FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab
